After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...

First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has granted clearance to a next-generation ...

The Dexcom G7 continuous glucose monitor (CGM) is as accurate or better than other currently marketed CGM devices for measuring glucose in those with diabetes, new data from a pivotal study suggest.

Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...

When it comes to the diabetes space, Dexcom is one of the heavy hitters. Its work in the continuous glucose monitoring space has put it on the map. In 2018, its Dexcom G6, an integrated continuous ...

DexCom, Inc. DXCM announced that its latest G7 continuous glucose monitoring (CGM) system can now connect with Tandem Diabetes Care's t:slim X2 insulin pump featuring Control-IQ technology. This ...

Dexcom announced last week that its G7 continuous glucose monitoring system has received FDA clearance. The latest model of its CGM, which can be used by people with all types of diabetes ages 2 and ...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE ...

The Dexcom G7 continuous glucose monitoring (CGM) system has been granted a CE Mark (Conformité Européenne), which means it is approved for use in people with diabetes in Europe aged 2 years and older ...

SAN DIEGO & ACTON, Mass.--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreement to combine current and future Dexcom ...